Optune Lua, formerly known as NovoTTF-100L, is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) ...

The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...

Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy Ministry ...

Optune Lua, formerly known as NovoTTF-100L, was approved by the FDA one year ago and is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years “We are proud of the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua through the country’s National Health Insurance program. In Japan, Optune ...

(RTTNews) - Novocure (NVCR) announced that Japan's Ministry of Health, Labour and Welfare approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Optune Lua received a CE Mark for treating metastatic NSCLC, used with immune checkpoint inhibitors or docetaxel after progression on a platinum-based regimen. The phase 3 LUNAR trial showed ...

BAAR, Switzerland, March 02, 2026--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua ® through the ...

NovoCure develops and markets devices that emit electrical fields in an effort to shrink tumors. The company's lead product at the moment, Optune, is a battery-powered hat that's approved to treat ...